Browse News
Filter News
Found 809,079 articles
-
Despite being hit with a continuing decline in COVID-19 sales and a strong Swiss franc, Roche on Wednesday reported first-quarter sales were up 2% at constant exchange rates.
-
The FDA on Tuesday approved Day One Biopharmaceuticals’ type II RAF inhibitor Ojemda, which is designed to penetrate the blood-brain barrier, for the treatment of relapsed or refractory pediatric low-grade glioma.
-
An undisclosed once-daily oral dose of Neurocrine Biosciences’ Takeda-partnered investigational drug significantly reduced symptom severity in adults with major depressive disorder.
-
Policy changes by health insurance companies will likely determine which Humira biosimilars rise to the top.
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
Thermo Fisher Scientific Reports First Quarter 2024 Results
4/24/2024
Thermo Fisher Scientific Inc., the world leader in serving science, reported its financial results for the first quarter ended March 30, 2024.
-
Harness Therapeutics Appoints Seasoned Biopharmaceutical Leader, Ms. Meenu Chhabra Karson, as Board Chair
4/24/2024
Harness Therapeutics, a biotechnology company focused on protein upregulation to develop next generation therapeutics for neurodegenerative diseases, announced the appointment of Ms. Meenu Chhabra Karson as Chair of its Board of Directors.
-
BioInvent International AB: Interim Report January-March 2024
4/24/2024
During the first quarter of the year, we continued making excellent progress with our clinical pipeline targeting TNFR2 and FcyRIIB, building on the momentum we generated during a very successful 2023.
-
Xaira Therapeutics Launches to Deliver Transformative Medicines by Advancing and Harnessing AI for Drug Discovery and Development
4/24/2024
Xaira Therapeutics launched on a mission to help re-engineer the way we discover and develop medicines through the end-to-end application of emerging AI technologies.
-
Spago Nanomedical Reports Favorable Data in Breast Cancer Model with Tumorad
4/24/2024
Spago Nanomedical AB announced data from a non-clinical study exploring 177Lu-SN201 in a model for triple-negative breast cancer.
-
Esaote Group: Shareholders' Meeting approves financial statements as of 31 December 2023
4/24/2024
The Shareholders' Meeting of Esaote S.p.A., met in Genoa, approved the company's financial statements as of 31.12.2023.
-
Angle PLC Announces New Commercial Agreement with AstraZeneca
4/24/2024
ANGLE plc, a world-leading liquid biopsy company with innovative circulating tumour cell solutions for use in research, drug development and clinical oncology has signed a supplier agreement with the global biopharmaceutical company, AstraZeneca PLC, to develop and validate a methodology leveraging ANGLE's existing DNA damage response assay for the detection of micronuclei in CTCs as a measure of DDR.
-
AAVantgarde announces updated NHP data from its Stargardt disease program in a poster presentation at the ARVO 2024 annual meeting
4/24/2024
AAVantgarde Bio announces the publication of an abstract submitted to The Association for Research in Vision and Ophthalmology Annual Meeting, to be held May 5-9 in Seattle.
-
Atom Bioscience Enrolling Patients in US as Part of a Global Phase 2b/3 Clinical Trial of a New Investigational Treatment for Chronic Gout
4/24/2024
Atom Bioscience, a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases, has begun enrolling patients in the US for in a Phase 2b/3 clinical trial of ABP-671, a novel investigational orally administered URAT1 inhibitor, for the treatment of chronic gout.
-
Evotec Presents Fiscal Year 2023 Results and Announces Priority Reset to Focus on Profitable Growth
4/24/2024
Evotec SE reported financial results and corporate updates for the fiscal year ended 31 December 2023 and announced a priority reset to optimise its business to meet evolving market demand and focus on profitable growth in 2024 and beyond.
-
Kuros Reports Corporate Highlights as of Q1 2024 Including Increase in Direct MagnetOsTM Sales
4/24/2024
Kuros Biosciences, a leader in advanced bone healing technologies, announced its financial performance for the first quarter of 2024.
-
ITRI Sweeps 2024 Edison Awards with Four Groundbreaking Innovations
4/24/2024
The Industrial Technology Research Institute triumphed at the recent Edison Awards™ in Fort Myers, Florida, securing recognition for four exceptional technological breakthroughs: the Novel Dual-Targeted Therapy for Glaucoma, Key Functional Cell Identity, PureTex Sustainable Decolorization Solution, and the High Resolution Full-Color Micro LED Display.
-
Nicox: Second notice of the Ordinary and Extraordinary Shareholders' Meeting on May 6, 2024 and appointment of an ad hoc agent
4/24/2024
Nicox SA informs its shareholders that the Ordinary and Extraordinary General Meeting, having been unable to deliberate on April 10, 2024 as the quorum required by law has not been reached, will be held, on second convening, on Monday May 6, 2024 at 2:30 p.m., at the offices of BuroClub - Drakkar 2 Bâtiment D - 2405 route des Dolines - 06560 Valbonne Sophia Antipolis.
-
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance
4/24/2024
Ipsen, a global specialty-care biopharmaceutical company, presents its sales for the first quarter of 2024.
-
Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards
4/24/2024
Pharming Group N.V. is pleased to announce its recognition as an Industry Innovator by the National Organization for Rare Disorders at the Rare Impact Awards on June 8, 2024.